Cipla Gains 2%: USFDA Clears InvaGen New York Plant
💊 CIPLA rose about 2.1% to ₹1,417.50 on 18 Nov 2026, even as the Nifty fell 0.63% on profit booking. The trigger: the USFDA has classified the recent inspection of its US subsidiary InvaGen's New York facility as "No Action Indicated" (NAI). What this opinion covers: ✅ The routine cGMP inspection at InvaGen's Hauppauge, Long Island plant ran from 19 to 22 Oct 2026 and ended with zero Form 483 observations ✅ NAI is the cleanest USFDA outcome: no objectionable conditions were found ✅ InvaGen is a wholly owned subsidiary and part of Cipla's US generics supply base ✅ Pharma was one of only 3 of 16 sectoral indices to close in the green on a weak day ✅ What to track next: new US product approvals, compliance status of other plants, and the US sales trend in upcoming quarters Why it matters: for Indian pharma companies, a clean regulatory record at US plants supports timely product launches and lowers compliance risk. Regulatory outcomes are one input; valuation, pricing pressure and the product pipeline matter too. 💬 Do you check USFDA inspection outcomes before studying a pharma stock? Share your view in the comments! 📲 For daily market notes, search "Neha Gupta SEBI RA" on Telegram and join the FREE channel. Neha Gupta | SEBI Registered Research Analyst | Reg. No. INH000016542 ⚠️ Disclaimer: This content is for educational purposes only and is not investment advice or a buy/sell recommendation. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.



















